{"doi":"10.1002/cam4.3395","title":"Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Prostate cancer screening incurs a high risk of overdiagnosis and overtreatment. An organized and age‐targeted screening strategy may reduce the associated harms while retaining or enhancing the benefits.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Using a micro‐simulation analysis (MISCAN) model, we assessed the harms, benefits, and cost‐effectiveness of 230 prostate‐specific antigen (PSA) screening strategies in a Dutch population. Screening strategies were varied by screening start age (50, 51, 52, 53, 54, and 55), stop age (51‐69), and intervals (1, 2, 3, 4, 8, and single test). Costs and effects of each screening strategy were compared with a no‐screening scenario.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The most optimum strategy would be screening with 3‐year intervals at ages 55–64 resulting in an incremental cost‐effectiveness ratio (ICER) of €19 733 per QALY. This strategy predicted a 27% prostate cancer mortality reduction and 28 life years gained (LYG) per 1000 men; 36% of screen‐detected men were overdiagnosed. Sensitivity analyses did not substantially alter the optimal screening strategy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>PSA screening beyond age 64 is not cost‐effective and associated with a higher risk of overdiagnosis. Similarly, starting screening before age 55 is not a favored strategy based on our cost‐effectiveness analysis.</jats:p></jats:sec>","journal":"Cancer Medicine","year":2020,"id":629184,"datarank":0.49983067652628066,"base_score":3.332204510175204,"endowment":3.332204510175204,"self_citation_contribution":0.49983067652628066,"citation_network_contribution":0.0,"self_endowment_contribution":0.49983067652628066,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":27,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":385725,"name":"Eveline A.M. Heijnsdijk","orcid":"0000-0002-4890-6069","position":1,"is_corresponding":false},{"id":240071,"name":"Monique J. Roobol","orcid":"0000-0001-6967-1708","position":2,"is_corresponding":false},{"id":305675,"name":"Harry J. de Koning","orcid":"0000-0003-4682-3646","position":3,"is_corresponding":false},{"id":1629354,"name":"Abraham M. Getaneh","orcid":"0000-0001-6749-5763","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios","abstract":"Prostate cancer screening incurs a high risk of overdiagnosis and overtreatment. An organized and age‐targeted screening strategy may reduce the associated harms while retaining or enhancing the benefits.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32813910","pmcid":null,"openalex_id":null,"authors":[],"funders":[{"funder_name":"National Institutes of Health","grant_id":"5U01CA199338-02","title":"Modeling to Improve Prostate Cancer Outcomes Across Diverse Populations"}],"total_grants":1,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"CC BY NC ND","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3395","host_type":"GOLD"},{"url":"https://doi.org/10.1016/s2666-1683(20)32649-5","host_type":""},{"url":"https://doi.org/10.1002/cam4.3395","host_type":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/32813910","host_type":""},{"url":"http://dx.doi.org/10.1002/cam4.3395","host_type":""},{"url":"https://doaj.org/article/51d332cbfa1c4494aa5f8e1f28649226","host_type":""},{"url":"https://doaj.org/article/7cf0c03621de4c27bb0cc53c2b91e9c4","host_type":""},{"url":"https://pure.eur.nl/en/publications/d3347985-f0a5-4e41-8b44-eb6b5a8affe1","host_type":""},{"url":"https://dx.doi.org/10.1002/cam4.3395","host_type":""},{"url":"https://dx.doi.org/10.1016/s2666-1683(20)32649-5","host_type":""},{"url":"https://doi.org/https://doi.org/10.1002/cam4.3395","host_type":""}],"fields_of_study":["Medicine","Economics","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":[],"keywords":["Male","Cancer Research","Cost-Benefit Analysis","610","EMC NIHES-02-65-01","Medical Overuse","RC0254","SDG 3 - Good Health and Well-being","EMC MM-03-49-01","Biomarkers, Tumor","Humans","Mass Screening","cost-effectiveness","RC254-282","Early Detection of Cancer","Aged","Neoplasm Staging","Netherlands","harms and benefits","harms and benefits; cost‐effectiveness","RC0254 Neoplasms. Tumors. Oncology (including Cancer)","micro‐simulation","prostate‐specific antigen (PSA) screening","Neoplasms. Tumors. Oncology. Including cancer and carcinogens","Prostatic Neoplasms","Middle Aged","Models, Theoretical","prostate cancer","Diseases of the genitourinary system. Urology","micro-simulation","Oncology","Radiology Nuclear Medicine and imaging","Population Surveillance","RC870-923","prostate-specific antigen (PSA) screening","Cancer Prevention","Algorithms"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T17:22:31.012893Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}